SPIRE SIGN IN Register

Spirethoughts

Spire's six most recent Spirethoughts.

E-Bikes are gaining ground around the world, amidst controversy
Family cafés the answer to Finland’s aging society
Family cafés the answer to Finland’s aging society
Upskilling workforces for the 4th Industrial Revolution
Asia-Pacific nations poised to sign the world’s largest multi-lateral trade agreement, RCEP, in 2020
Asia-Pacific nations poised to sign the world’s largest multi-latera...
Eco-tourism creates ecological and economic benefits
Eco-tourism creates ecological and economic benefits
Ghana citizenships to boost economy

India’s generic drug industry heading for change

The India Supreme Court recently rejected drug maker Novartis AG’s attempt to patent an updated version of a cancer drug. This would ensure patients across the globe would have access to cheaper versions of lifesaving medicines, such as Glivec, that is used to treat chronic myeloid leukemia. With a generic and more affordable medicine available at a huge price difference, this could be the difference between life and death.

On the other hand, this decision also means that India’s USD26 billion generic drug industry, which supplies most cheap medicines across the developing world could slow down. Many other international pharmaceutical companies are now re-thinking their strategies for the Indian market. Nonetheless, it signifies that Indian companies will now have added legal coverage to produce and export low-cost generic drugs.

How would giving the world access to cheaper medicines affect India?

Back to Top

Back to Home
BTBTBTBTBTBT